Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability

Table 3 Univariable and multivariable logistic regression analyses depicting factors potentially associated with increased likelihood of infliximab infusion reaction/s with a rapid infusion protocol in this cohort (n = 129)

Variable	Univariable odds ratio (95%CI)	P value	Multivariable odds ratio (95%CI)	P value
Lower BMI (< 22 kg/m2)	2.0 (0.7, 6.0)	0.15	5.3 (1.3, 21.6)	0.02
Presence of ≥ 1 extra intestinal manifestation	4.0 (1.4, 11.8)	0.01	8.8 (2.3, 33.5)	< 0.01
Disease duration ≥ 3 yr	4.8 (1.1, 20.5)	0.01	6.1 (1.1, 35.1)	0.04
Previous infliximab exposure (≥ 1 dose)	5.8 (1.2, 27.2)	0.02
Previous other biologic exposure (any other agent)	18.6 (1.6, 218.0)	0.03	34.9 (2.1, 576.7)	0.01
Previous break off infliximab (≥ 3 m)	5.1 (1.3, 19.4)	0.03	4.8 (0.8, 28.4)	0.08
Concurrent immunomodulator (any)	0.1 (0.01, 1.1)	0.06
Concurrent thiopurine	0.3 (0.1, 1.001)	0.06
Previous adverse drug reaction (any)	2.2 (0.7, 6.7)	0.12
Known psychiatric comorbidity	2.4 (0.8, 6.7)	0.10
Pre-medication used	0.5 (0.3, 1.00)	0.08

Final multivariable model characteristics: Omnibus goodness of fit chi-square = 28.9, P < 0.001, Nagelkerke’s R² = 0.40. BMI: Body mass index.